Product Description: Liothyronine is an active form of thyroid hormone. Liothyronine binds to thyroid hormone receptors TRα and TRβ with Kis of 2.33 and 2.29 nM for hTRα and hTRβ, respectively. Liothyronine also binds to PVR and blocks the interaction of TIGIT/PVR[1][2][3].
Applications: Cancer-programmed cell death
Formula: C15H12I3NO4
Citations: Acta Pharmacol Sin. 2024 May 24./Adipocyte. 2022 Dec;11(1):84-98./Am J Physiol Endocrinol Metab. 2024 Apr 3./Cell Death Discov. 2022 Apr 30;8(1):236./Cell Metab. 2023 Sep 7;S1550-4131(23)00304-2./Cell Rep. 2024 Mar 18;43(3):113930./Eur J Med Chem. 2024 Mar 20:269:116344./Food Science and Human Wellness. 2023 Nov;12(6);2061-2072./J Med Chem. 2022 Jan 21./J Nutr Biochem. 2020 Apr;78:108335./J Therm Biol. 2024 Jul 2:123:103906./Methods Mol Biol. 2023;2683:103-111./Nat Commun. 2023 Jun 2;14(1):3208./Patent. US20220389379A1./J Ethnopharmacol. 2022 Aug 11;115622./JCI Insight. 2021 Jun 22;6(12):142838./Sci Adv. 2024 Feb 9;10(6):eadk3931.
References: [1]Lin KH, et al. Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. Cancer Lett. 1994 Oct 14;85(2):189-94./[2]Bhat MK, et al. Conformational changes of human beta 1 thyroid hormone receptor induced by binding of 3,3',5-triiodo-L-thyronine. Biochem Biophys Res Commun. 1993 Aug 31;195(1):385-92./[3]Hiroaki Shiohara, et al. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia. Bioorg Med Chem. 2012 Jun 1;20(11):3622-34./[4]Zhou X, et al. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR. Cell Commun Signal. 2020 Sep 7;18(1):142.
CAS Number: 6893-02-3
Molecular Weight: 650.97
Compound Purity: 99.82
Research Area: Cancer; Endocrinology
Solubility: 1M NaOH : 50 mg/mL (ultrasonic;warming;heat to 60°C)/DMSO : 50 mg/mL (ultrasonic)
Target: Endogenous Metabolite;Thyroid Hormone Receptor